1 / 5

Bone Sarcoma Biology: 20 years Later

Bone Sarcoma Biology: 20 years Later. Sarcomas with specific reciprocal translocations. Sarcomas with complex unbalanced karyotypes. Biology. Treatment (Prognostication). Biological Insights/Prognostic Factors. Important to identify and describe, even more critical will be to validate.

denali
Download Presentation

Bone Sarcoma Biology: 20 years Later

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bone Sarcoma Biology: 20 years Later Sarcomas with specific reciprocal translocations Sarcomas with complex unbalanced karyotypes Biology Treatment (Prognostication)

  2. Biological Insights/Prognostic Factors • Important to identify and describe, even more critical will be to validate. • Three interesting candidates in osteosarcoma presented. • Identified using very different modalities – integrative analysis, deep sequencing, proteomics.

  3. Tadashi Kondo Nalan Gokgoz 53 gene signature for outcome Peroxiredoxin2 correlates with response to induction Leonardo A. Meza-Zepeda RNA and DNA sequencing identified a translocation between chromosome 17 and 6, involving the PMP22 and ELOVL5 genes respectively.

  4. Therapeutic Approaches Francois Lamoureux Ymera Pignochino Inhibition of clusterin with OGX-011 is synergistic with zoledronate in osteosarcoma Trabectidin and PARP-1 inhibition is synergisic

  5. Randomized phase 2 trial in chondrosarcoma – Andrew Wagner • Hedgehog pathway - strong preclinical rationale • Appropriate design and PFS endpoint – challenging disease • The planned biology studies may help understand the trial results further

More Related